An interventional study of BrainSonix Pulsar 1002 in Depression, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies in Depression by Massachusetts General Hospital — 24 open to participants now, 33 under way, none of them phase 3. Depression · Massachusetts General Hospital.
Among the 163 studies in Depression by Massachusetts General Hospital, this one is the 57th largest by planned enrollment of the 153 interventional ones that give a count, is one of 5 that started in 2023, is one of 100 with no phase, reaches primary completion later than 3 of the 32 other live ones, and was the 123rd registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →24 of the 163 studies in Depression by Massachusetts General Hospital are open now, in 4 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in Nigeria
Ages 16–29
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 22 · Phase 3 9 · Phase 4 22
First in 2001; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 60 across the 153 interventional studies, 80 across the 10 observational. Of the 123 that completed or were terminated, 71 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
20 of the studies in Depression by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06094088Massachusetts General HospitalResearching Heat and Yoga for Mood Enhancement | 2026-12 |
| NCT04832685Massachusetts General HospitalNeuromodulation of Mind-Wandering in Depression | 2026-12 |
| NCT07892287Massachusetts General HospitalEffect of Neurofeedback and TMS | 2027-01 |
| NCT07639827Massachusetts General HospitalA Study of a Mental Fitness Intervention for Anesthesiology Resident Wellbeing and Self-Compassion | 2027-01 |
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 163 studies in Depression by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The specific aim of this proposed study is to investigate the feasibility and therapeutic potential of LIFUP in changing negative cognition in depression. Specifically, the investigators will study if modulating DMN activity can change maladaptive mind-wandering. The investigators hypothesize that DOWN-modulation of the posterior cingulate cortex (PCC), a key DMN node, will decrease DMN resting state functional connectivity, perfusion, and activation during a cognitive-affective task (description below). The investigators also hypothesize that DOWN-modulation of the PCC will be associated with decreased mind-wandering and increased mindfulness. Finally, the investigators hypothesize that the opposite will be true for UP-modulation of the PCC.
The default mode network (DMN) is a network of structurally and functionally connected brain regions that was first identified during "passive" states. Since its initial discovery, the conceptualization of the DMN has evolved over time; the DMN has now been linked with a range of higher-order cognitive processes such as spontaneous, self-generated thoughts (i.e. mind-wandering) and thinking about oneself in the past, future, and in relation to others. Given the DMN's involvement in cognition, researchers have investigated its role in psychiatric disorders associated with cognitive issues, such as Major Depressive Disorder (MDD).
MDD is a mood disorder in which people experience a persistent negative mood or loss of interest or pleasure, thoughts of worthlessness and guilt, and/or suicidal ideation. The majority of literature suggests that currently depressed individuals have increased DMN resting-state functional connectivity at rest and greater DMN activation when processing negative stimuli. Researchers have suggested that this DMN hyperactivity reflects the tendency for depressed individuals to engage in negative cognition, such as maladaptive mind-wandering (i.e. task-irrelevant thought when individuals are supposed to be focused on a task) and rumination (i.e. negative, repetitive, self-focused thinking). Mind-wandering, in general, has been linked to unhappiness. Rumination is associated with the maintenance of a current depressive episode and is a predictor of future depressive episodes. Therefore, changing these forms of negative cognition, via modulation of DMN activity, could be of benefit to individuals with MDD.
One way of modulating DMN activity is to use brain stimulation. The investigators have previously used transcranial Direct Current Stimulation (tDCS) of a DMN brain region to effect a small yet significant reduction in mind-wandering behavior in a community sample. However, tDCS has low spatial specificity and neuroimaging was not used to determine if tDCS was actually changing mind-wandering via changes in DMN activity. Low Intensity Focused Ultrasound Pulsation (LIFUP) is a novel non-invasive brain stimulation method which has high spatial specificity, unlike other non-invasive brain stimulation methods such as Transcranial Magnetic Stimulation (TMS) and tDCS. Specifically, LIFUP can deliver acoustic energy to a brain region of a few millimeters in diameter. This method has been applied to the thalamus to restore consciousness to patients in minimally conscious states, and the investigators have been using this method in multiple IRB-approved studies as applied to the amygdala, ventral striatum, and entorhinal cortex.
Specific Aims:
The specific aim of this proposed study is to investigate the feasibility and therapeutic potential of LIFUP in changing negative cognition in depression. Specifically, the investigators will study if modulating DMN activity can change maladaptive mind-wandering. The investigators hypothesize that DOWN-modulation of the posterior cingulate cortex (PCC), a key DMN node, will decrease DMN resting state functional connectivity, perfusion, and activation during a cognitive-affective task (description below). The investigators also hypothesize that DOWN-modulation of the PCC will be associated with decreased mind-wandering and increased mindfulness. Finally, the investigators hypothesize that the opposite will be true for UP-modulation of the PCC.
Subject Selection:
Twenty participants (n = 40 healthy controls, n = 40 individuals with MDD) aged 18-64 years old will be recruited. The Structured Clinical Interview for DSM-5 Disorders, Research Version (SCID-5-RV)10 will be used to determine eligibility.
Subject Enrollment:
Participants will be recruited through email announcements at MGH, postings to college websites, and flyers (see attached flyer) posted at MGH and in the community (e.g., community centers, public libraries, coffee shops, restaurants, and laundromats). A phone screening will be performed to efficiently confirm likelihood that subjects will meet inclusion and exclusion criteria prior to committing time for further evaluation of eligibility.
Informed consent will be obtained prior to the performance of any protocol procedures. The informed consent document will be used to explain in simple terms the risks and benefits of study participation to the subject. The nature of the study will be fully explained to the subject by the PI, co-investigators or specially-trained study staff. The subject will be encouraged to ask questions pertaining to their participation in the study and the subject may take as much time as they feel necessary to consider his/her participation in the study as well as consult with family members or their physicians. Participation in this study is voluntary and the subjects may withdraw from the study at any time. The IRB-approved informed consent documents will be signed and dated by the subject and the person obtaining consent.
Study Procedures:
After providing study information and obtaining IRB approved informed consent, participants will complete up to five study visits on five different days.
Visit 1 (up to 1 hour):
For participants who are recruited as healthy controls, the SCID-5-RV will be administered to determine if the participant has no current or past history of any psychiatric disorders. For participants who are recruited as individuals with MDD, the SCID-5-RV will be administered to determine if the participant meets criteria for a current MDD diagnosis. Participants will be excluded from further study procedures if they do not meet the above-described criteria.
Visit 2 (up to 1 hour):
Participants will complete questionnaires assessing depressive symptoms, anxiety, mindfulness, and rumination.
After completing questionnaires, participants will practice the cognitive task they will be performing in the MRI scanner. Participants will complete a self-attribution task (Ghaznavi, Chou, Dougherty, \& Nierenberg, 2023). Participants will see a series of trait adjectives and be asked to make a judgment about whether that personality trait applies to them (i.e. press a button indicating "Me" or "Not Me"). This task has been used by our lab to assess cognition and DMN activation in bipolar disorder.
After completing the practice computer task, participants will complete the MR Screening Safety form. After confirming the participant does not have MRI contraindications, they will be scanned using a 3 Tesla Siemens MRI scanner at the Athinoula A. Martinos Center for Biomedical Imaging. At baseline, we will collect a T1 MEMPRAGE structural scan, blood-oxygen-level-dependent (BOLD) resting state scan, Arterial Spin Labelled (ASL) scan, and a BOLD functional MRI scan paired with the task (described above). Participants will then exit the MRI scanner and will be asked to retrospectively report on their mind-wandering thoughts during the task. Participants will not receive LIFUP during this visit.
Visits 3 and 4 (up to 3.5 hours each; spaced 1 week apart):
At Visits 3 and 4, participants will complete the same questionnaires (described in Visit 2). To assess the subjective experience of LIFUP and its effects on mood, participants will rate their negative and positive mood on Visual Analog Scales as well as complete the 11-factor Altered States of Consciousness questionnaire (ASC) after LIFUP.
Participants will be scanned again with the same MRI sequences and complete the same computer task described in Visit 2, pre and post LIFUP.
LIFUP Sonication:
Participants will be fitted with the LIFUP device, the BX Pulsar 1002 (BrainSonix Corporation). The transducer will be placed on the head using landmarks and will be targeting the cluster in the PCC that was activated during the computer task in Visit 2. Participants will then receive either active or sham DOWN-modulation (Pulse Repetition Frequency = 10 Hz, Pulse-Width = 0.5 ms, Duty Cycle = 5%, ISPPA = 14.4 mW/cm2, 720 mW/cm2). The order will be counterbalanced across subjects. The sonications will be delivered in a 30-seconds on, 30-seconds off block design, for a total duration of 10 minutes. We are using the same LIFUP parameters in other IRB-approved LIFUP studies (IRB protocol #2019P000562 and IRB protocol #2019P001458) and these parameters have been safely used at other research collaborator sites at UCLA and MUSC. For sham sonication, a gel pad that absorbs ultrasound will be used with the transducer so that the ultrasound will not go through the skull and into the brain. For active sonication, a gel pad that allows the transmission of ultrasound waves will be used with the transducer. These gel pads look identical; this study will be double-blinded where study staff will not know which gel pad corresponded with active or sham LIFUP.
Visit 5 (up to 1 hour; spaced 1 week after Visit 4):
During this visit, participants will complete the same questionnaires (described in Visit 2).
Biostatistical Analysis:
fMRI data during the task will be analyzed using SPM12 software (Wellcome Department of Cognitive Neurology, London, UK). Individual subject-level data will be slice-time corrected, realigned and unwarped, coregistered to the individual's structural images, normalized, and smoothed. For LIFUP targeting, first-level contrast images will be created to identify BOLD activation in the PCC during self-judgments. To study the effects of LIFUP, first-level contrast images will be created comparing BOLD activation during the task before and after LIFUP. These contrast images will then be entered into a 2nd level random effects flexible factorial model. We will investigate whether there is a group (MDD versus healthy control) by condition (sham vs. active modulation) interaction on BOLD activation in DMN regions. Beta signal values will be extracted from DMN regions and we will investigate if there are significant correlations between DMN activation and our behavioral measures of depressive symptoms, anxiety, and mindfulness/mind-wandering.
BOLD resting state scan data will be similarly preprocessed and entered into CONN toolbox. The PCC will be used as a seed region and Fischer-transformed functional connectivity beta values with other DMN regions will be extracted for each individual subject. Repeated-measures ANOVAs will be conducted to again investigate whether there is a group by condition interaction on DMN resting state functional connectivity. Correlational analyses will also be performed to explore correlations with behavioral measures.
ASL data will be analyzed using Bayesian Inference for Arterial Spin Labeling MRI. Perfusion maps corresponding to pre and post LIFUP will be subtracted from each other to determine if there is decreased or increased perfusion in DMN regions associated with active modulation.
An updated statistical power analysis from our recent LIFUP study of the amygdala suggests that 40 participants will be necessary to achieve statistical significance (p \< 0.05) in a voxel-based analysis. To increase our statistical power for comparing two groups, we will recruit 40 participants in each group (total n = 80).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive active modulation of the posterior cingulate cortex (PCC) during Visit 3 or 4 (order counterbalanced).
Device: BrainSonix Pulsar 1002
All participants will receive sham modulation of the posterior cingulate cortex (PCC) during Visit 3 or 4 (order counterbalanced).
Device: BrainSonix Pulsar 1002
Device that delivers low intensity focused ultrasound
Negative self-judgment frequency during task
Changes in reported frequency of negative self-judgments during the self-attribution task before and after sham and active modulation
Time frame: 3 hours
Default mode network activation during task
Changes in Blood-Oxygen-Level Dependent activation in the default mode network during the self-attribution task before and after sham and active modulation
Time frame: 3 hours
Rumination
Changes in Ruminative Responses Scale scores after the sham and active modulation sessions
Time frame: 1 week
Depressive symptoms
Depressive symptoms as measured by the Beck Depression Inventory in the week after the active session
Time frame: 1 week
Default mode network connectivity
Changes in default mode network resting state functional connectivity before and after sham and active modulation
Time frame: 3 hours
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 45 months is above that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →